Overview

In Vivo Performance of Oral Liquid Formulations of Budesonide in the Fasted State in Healthy Subjects

Status:
Completed
Trial end date:
2019-01-29
Target enrollment:
Participant gender:
Summary
This is a single centre, open-label, sequential, single dose 4-period crossover, scintigraphic imaging study in healthy male and non-pregnant, non-lactating female subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Sandoz
Treatments:
Budesonide